Literature DB >> 3789744

Evidence for the presence of an N-acetyllactosamine-type chain in epiglycanin.

J F Codington, M R Deak, D M Frim, R W Jeanloz.   

Abstract

Mannose-labeled epiglycanin was prepared by incubation of TA3-Ha ascites cells with [2-3H]mannose, removal of the epiglycanin by incubation of viable cells with L-1-p-tosylamino-2-phenylethyl chloromethyl ketone-trypsin, and isolation of the large epiglycanin glycopeptides by gel filtration. Purification of epiglycanin glycopeptides was performed by wheat germ agglutinin affinity chromatography. Extensive incubation of epiglycanin with Pronase, followed by passage through a calibrated column of Bio-Gel P-4 (Column P-4), gave three fractions. The fraction of lowest apparent molecular weight, about 5000, upon incubation with a purified extract from F. meningosepticum containing an N-glycosyl hydrolase and an endo-N-acetyl-beta-D-glucosaminidase (T.H. Plummer et. al. (1984) J. Biol. Chem. 259, 10700-10704) and passage through Column P-4 gave a peak of radioactivity at apparent Mr 3000. Incubation of nonlabeled epiglycanin under similar conditions with the same enzyme preparation followed by passage through Column P-4, gave two peaks, based upon total mannose content. One of these, partially deglycosylated epiglycanin, was present in the void volume. Its composition indicated that approximately 80% of the mannose content of epiglycanin had been removed by the enzyme treatment, whereas no change was noted in the proportion of the other carbohydrate components. The effluent volume of the second peak coincided precisely with the peak obtained from the Pronase-cleaved fraction. Its composition and apparent Mr were consistent with those of an N-lactosamine-type chain with four antennae, Man3Gal4GlcNAc5NeuAc2-3.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789744     DOI: 10.1016/0003-9861(86)90049-4

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  3 in total

1.  Specificity studies of an antibody developed against a mucin-type glycoprotein.

Authors:  S Haavik; M Nilsen; T Thingstad; H Barsett; D V Renouf; E F Hounsell; J F Codington
Journal:  Glycoconj J       Date:  1999-03       Impact factor: 2.916

2.  Biosynthesis and shedding of epiglycanin: a mucin-type glycoprotein of the mouse TA3Ha mammary carcinoma cell.

Authors:  T Thingstad; H L Vos; J Hilkens
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

3.  The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.

Authors:  H Kemperman; Y Wijnands; J Wesseling; C M Niessen; A Sonnenberg; E Roos
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.